Zhejiang East Asia Pharmaceutical
Launch date
Employees
Market cap
$260m
Enterprise valuation
$308m (Public information from Sep 2024)
Share price
CNY16.37 605177.SS
Taizhou Jiangsu (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 988m | 882m | 712m | 1.2b | 1.4b |
| % growth | - | (11 %) | (19 %) | 66 % | 15 % |
| EBITDA | 262m | 196m | 153m | 212m | 264m |
| % EBITDA margin | 27 % | 22 % | 21 % | 18 % | 19 % |
| Profit | 168m | 114m | 68.5m | 104m | 121m |
| % profit margin | 17 % | 13 % | 10 % | 9 % | 9 % |
| R&D budget | 37.2m | 38.4m | 37.3m | 44.9m | 81.7m |
| R&D % of revenue | 4 % | 4 % | 5 % | 4 % | 6 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
